NCT01535157 2020-08-27
Fenretinide/LXS Oral Powder Plus Ketoconazole in Recurrent Ovarian Cancer
South Plains Oncology Consortium
Phase 1/2 Terminated
Clinical Trials
5 trialsNCT00003075 2018-10-24
Fenretinide in Treating Patients With Cervical Neoplasia
M.D. Anderson Cancer Center
Phase 3 Completed
NCT00017134 2013-06-10
Fenretinide Followed by Surgery Compared With Surgery Alone in Preventing Ovarian Cancer in Patients at Increased Risk
GOG Foundation
Phase NA Terminated
NCT00026091 2013-03-25
Fenretinide in Treating Patients With Recurrent or Metastatic Ovarian Epithelial or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00098800 2010-03-24
Fenretinide in Preventing Ovarian Cancer in Participants Who Are at High Risk for Developing Ovarian Cancer and Planning to Undergo Surgery to Remove the Ovaries
University of Arizona
Phase NA Completed